Claims for Patent: 4,959,314

Summary for Patent: 4,959,314

Title:	Cysteine-depleted muteins of biologically active proteins
Abstract:	Muteins of biologically active proteins such as IFN-.beta. and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect intramolecular disulfide bridge formation. These muteins are made via bacterial expression of mutant genes that encode the muteins that have been synthesized from the genes for the parent proteins by oligonucleotide-directed mutagenesis.
Inventor(s):	Mark; David F. (Danville, CA), Lin; Leo S. (Fremont, CA), Yu Lu; Shi-da (Oakland, CA), Wang; Alice M. (Walnut Creek, CA)
Assignee:	Cetus Corporation (Emeryville, CA)
Application Number:	06/698,939
Patent Claims:	1. A synthetic mutein of a biologically active native protein which native protein has at least one cysteine residue that is free to form a disulfide link and is nonessential to said biological activity, said mutein having at least one of said cysteine residues substituted by another amino acid and said mutein exhibiting the biological activity of said native protein. 2. The synthetic mutein of claim 1 wherein there is only one of said cysteine residues comprised in the biologically active native proteins. 3. The synthetic mutein of claim 1 wherein said cysteine residues are replaced by serine, threonine, glycine, alanine, valine, leucine, isoleucine, tyrosine, phenylalanine, tryptophan, or methionine. 4. The synthetic mutein of claim 1 wherein said cysteine residues are replaced by serine or threonine. 5. The synthetic mutein of claim 1 wherein the mutein is unglycosylated. 6. A therapeutic formulation comprising an effective amount of the mutein of claims 1, 2, 3, 4 or 5, and at least one other anti-cancer or anti-viral compound. 7. The formulation of claim 6 wherein the anti-cancer or anti-viral compound is gamma interferon. 8. A structural gene having a DNA sequence that encodes a synthetic mutein of a biologically active native protein which native protein has at least one cysteine residue that is free to form a disulfide link and is nonessential to said biologically activity, said native mutein having at least one of said cysteine residues substituted by another amino acid and said mutein exhibiting the biological activity of said native protein. 9. A structural gene having a DNA sequence that encodes the synthetic mutein of claim 8 wherein there is only one of said cysteine residues comprised in the biologically active native protein. 10. A structural gene having a DNA sequence that encodes the synthetic mutein of claim 8 wherein said cysteine residues are substituted by serine, threonine, glycine, alanine, valine, leucine, isoleucine, histidine, tyrosine, phenylalanine, tryptophan or methionine. 11. A structural gene having a DNA sequence that encodes the synthetic mutein of claim 8 wherein said cysteine residues are substituted by serine or threonine. 12. A structural gene having a DNA sequence that encodes the synthetic mutein of claim 8 wherein the mutein is unglycosylated. 13. An expression vector that includes the structural gene of claim 1, 9, 10, 11 or 12 in a position that permits expression thereof. 14. A host cell or organism transformed with the expression vector of claim 13 and progeny thereof. 15. E.coli transformed with the expression vector of claim 13 and progeny thereof. 16. A process for making a synthetic mutein comprising culturing the host or progeny of claim 14 and harvesting the synthetic mutein from the culture. 17. A method for making a gene having a DNA sequence that encodes a synthetic mutein of a biologically active native protein which native protein has at least one cysteine residue that is free to form a disulfide link and is non-essential to said biological activity, said mutein having at least one of said cysteine residues substituted by another amino acid and said mutein exhibiting the biological activity of said native protein comprising: (a) hybridizing single-stranded DNA comprising a strand of a structural gene that encodes said protein with a mutant oligonucleotide primer that is complementary to a region of said strand that includes the codon for said cysteine residue or the anti-sense triplet paired with said codon, as the case may be, except for a mismatch with said codon or said antisense triplet which mismatch defines a triplet that codes for said other amino acid; (b) extending the primer with DNA polymerizes to form a mutational heteroduplex; and (c) replicating said mutational heteroduplex 18. The method for making the gene of claim 17 wherein the synthetic mutein has only one of said cysteine residues. 19. The method for making the gene of claim 17 wherein said cysteines of the synthetic mutein are substituted by serine, threonine, glycine, alanine, valine, leucine, isoleucine, histidine, tyrosine, phenylalanine, tryptophan or methionine. 20. The method of claim 17 or 18 wherein the mismatch defines a triplet that codes for serine or threonine. 21. The method of claim 17, 18 or 19 wherein the single-stranded DNA is a single-stranded phage that includes said strand and the mutational heteroduplex of step (b) is converted to closed circular heteroduplex. 22. The method of claim 17, 18 or 19 wherein said replicating is effected by transforming a competent bacterial host with the closed circular heteroduplex and culturing the resulting transformants.

Details for Patent 4,959,314

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993		2002-10-19

International Patent Family for US Patent 4,959,314

Country	Patent Number	Estimated Expiration
Austria	54941
Austria	60798
Australia	5010685
Australia	5518086
Australia	589919
Bulgaria	60238